Processing breakthroughs and big funding deals drive Week 14 winners

• Globe Metals & Mining (ASX:GBE) surged on a US$1.025b NPV niobium study and a staged build plan.
• American Uranium (ASX:AMU) jumped after a larger uranium resource and a clear timeline to a Q3 2026 scoping study.
• KGL Resources (ASX:KGL) rallied after landing a US$300m streaming deal that avoids normal loan repayments.
• Some gapped re-openings kept sliding, showing buyers stepped away after the first burst of trading.

Globe Metals & Mining (ASX:GBE) led the week with 55.91% after releasing a Bankable Feasibility Study for its Kanyika Niobium Project in Malawi. Investors chased the size of the numbers: a post-tax NPV of US$1.025 billion and a 48% IRR, plus a phased build that starts smaller before expanding. American Uranium (ASX:AMU) followed with 38.10%, after lifting its Lo Herma resource to 9.45Mlbs and raising the share of higher-confidence “Indicated” tonnes to 43% (meaning the estimate is based on tighter drilling and is generally seen as more reliable). KGL Resources (ASX:KGL) gained 35.90% after signing a US$300 million streaming deal with Wheaton Precious Metals, which is a funding method where the investor pays upfront and later buys a share of by-product metal at an agreed price.

Critical minerals: processing wins and big economics

Processing news did a lot of the heavy lifting in rare earths and specialist metals. Victory Metals (ASX:VTM) rose 10.49% after reporting more than 70% extraction of heavy rare earths at North Stanmore using leaching at atmospheric pressure. In plain terms: the company says it can pull out valuable elements without the expensive high-temperature steps that often blow out build costs. MRG Metals (ASX:MRQ) reported early testwork recovering about 72% of monazite concentrate at Garies, but trading after its re-opening didn’t hold. Early selling pushed it lower from the re-open level, which can happen when investors decide the result still needs more proof on scale and cost. Rare earth financing also tightened the gap between “good project” and “funded project”. Arafura Rare Earths (ASX:ARU) added 11.11% after locking in ~A$230 million in binding cornerstone equity from German and Australian government-backed funds. That matters because Nolans is a large build, and equity cheques reduce the risk of the project stalling for lack of cash.

Money on the table: streaming, placements and entitlement offers

Several moves were driven by funding structures rather than drill bits. KGL’s streaming deal was treated as a positive because it brings in a large lump of cash without the normal “repay principal every quarter” pressure of a bank loan. St Barbara (ASX:SBM) climbed 11.40% after confirming A$389 million cash received from Lingbao Gold Group and approving a US$333 million New Simberi expansion. Investors tend to like “fully funded” language because it lowers the chance of a surprise capital raising later. By contrast, some equity raisings weighed on prices even when the strategy sounded sensible. KMD Brands (ASX:KMD) fell -25.72% after announcing a discounted equity raising and refinancing. After the stock re-opened, it did bounce from the first traded price, but it still finished the week sharply down. That’s a common pattern when new shares are issued cheaply, because existing holders worry their slice of the company gets smaller.

Gold and copper: bigger resources, longer mine lives

Copper and gold names also found buyers on tangible growth. AIC Mines (ASX:A1M) jumped 17.39% after lifting resources and reserves at Eloise and Jericho, which points to longer operating life and more throughput once its plant expansion arrives in late 2026. Antipa Minerals (ASX:AZY) rose 4.55% after expanding Minyari to 3.6Moz gold equivalent, with 85% of the core Minyari Dome deposits now in the higher-confidence Indicated category. Big tungsten results also hit the tape. Greatland Resources (ASX:GGP) climbed 31.66% after publishing a 70Mt tungsten resource at O’Callaghans, supported by extensive drilling and close to existing infrastructure. Viking Mines (ASX:VKA) reported a 53-fold upgrade to a 63.6% WO3 concentrate and finished up 3.70%, as investors responded to the idea that simple processing could keep start-up costs lower.

Healthcare and tech: regulation and benchmarks move prices

In healthcare, regulatory decisions and supply chain links drove sharp reactions. Atomo Diagnostics (ASX:AT1) dropped -20.00% even though Lumos’s FebriDx gained a US FDA CLIA waiver (a permission that allows the test to be used more widely outside big labs). The sell-off suggests holders focused on near-term uncertainty, like how fast orders convert into cash for Atomo, and how quickly production can scale. Lumos Diagnostics (ASX:LDX) also fell -17.65% despite landing a US$1.3 million FebriDx order, showing investors can still worry about working capital and the pace of repeat buying. Tech performance claims also attracted attention. FortifAI (ASX:FTI) rose 11.11% after saying its Nol8 technology ran far faster than Google’s RE2 engine under heavy AI-style workloads. Investors care about this because faster data handling can mean lower server cost for customers, but the next test will be whether the company can turn benchmarks into signed enterprise contracts.

When bad news lands: legal risk and “air pocket” re-openings

A few stocks showed what happens when the first traded price after a halt can’t attract steady buying. Syrah Resources (ASX:SYR) ended down -8.00% as it launched a A$104 million retail entitlement offer. Investors often step back during entitlement offers because they want to see how many holders take up new shares, and whether the raising leaves the company with enough cash to hit its ramp-up plans. Legal headlines also hit sentiment fast. ARN Media (ASX:A1N) slid -18.97% after disclosing an $82 million-plus claim tied to alleged adverse action and bullying. Markets typically mark these situations down because outcomes are uncertain, legal costs can mount, and management attention is pulled away from running the business.

Bottom Line?

April through June 2026 is shaping up as a catalyst-heavy window: Greatland (ASX:GGP) and Globe Metals (ASX:GBE) will be judged on follow-up work and funding progress after eye-catching studies, while healthcare names tied to FebriDx face a practical test on US order flow after the CLIA waiver. In energy, AGL (ASX:AGL) has flagged construction starting mid-2026 on its Kwinana gas project, which will be watched for cost and schedule updates.

Questions in the middle?

• Will Globe Metals (ASX:GBE) convert non-binding interest into binding offtake and funding, and on what terms?
• How quickly will FebriDx demand turn into steady, repeat orders — and can Atomo (ASX:AT1) scale cassette supply without margin pressure?
• Does Syrah (ASX:SYR) emerge from its entitlement offer with enough cash to lift output at Balama and Vidalia, or will it need more support later in 2026?